Clinical trials

  • CLOPIDOGREL for Systemic sclerosis | Raynaud phenomenon
  • Capmatinib for cMET-dependent malignancies | Advanced cancer
  • DOSTARLIMAB for Non-mucinous epithelial ovarian cancer (stage III or IV)
  • LUTETIUM (177LU) OXODOTREOTIDE for Neuroendocrine tumor | Intestinal well-differentiated neuroendocrine tumor
  • BEVACIZUMAB for Brain radionecrosis | Brain metastases
  • 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID for Alexander disease
  • ZOLBETUXIMAB for Metastatic pancreatic adenocarcinoma
  • Methylprednisolone for Acute myocarditis
  • AZD0901 (Sonesitatug vedotin) for Locally advanced unresectable or metastatic gastric adenocarcinoma | Locally advanced unresectable or metastatic gastroesophageal junction adenocarcinoma
  • LORAZEPAM for Dementia | Agitated behaviour
  • Fluorouracil for Ampullary adenocarcinoma
  • TESTOSTERONE for Low ovarian reserve | Androgen receptor polymorphism